734 Weekly Paclitaxel as Salvage Therapy in Recurrent Ovarian Cancer

Objective: to estimate the activity and toxicity of weekly paclitaxel as salvage therapy in women with recurrent ovarian carcinoma. Methods: We retrospectively reviewed the medical records of women with recurrent epithelial ovarian cancer treated between July 2002 and May 2004 with single-agent weekly intravenous paclitaxel (60 mg/sq, 1-hour infusion) at University of Bari. Fifteen patients with a median age of 51 years (range 26-71) were treated with single agent paclitaxel. All patients had previously received multiple systemic chemotherapy regimens, including paclitaxel for a median of six cycles. in 8 patients, this drug was the fourth line of therapy, in 5 it was the fifth line, in two the sixth. Results: Four patients are still on treatment and are evaluable only for toxicity. A median of 20 cycles of weekly paclitaxel (range 6-68) were administered. Treatment was delayed in only one patient (7%) (for neutrophil count